Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-Williams class III antiarrhythmic agents in experimental models. To test the efficacy of Sotalol to suppress ventricular arrhythmias, a 6 week parallel, placebo-controlled outpatient study of two doses (320 and 640 mg/day, in two divided doses) was performed in four hospitals in 56 patients with chronic premature ventricular complexes at a frequency of 30/h or more (mean ± SE, 528 ± 60/h) on 48 hour ambulatory electrocardiographic recording. During a placebo week, no change occurred in arrhythmia frequency (532 ± 76/h). Subsequent Sotalol therapy significantly reduced median arrhythmia frequency in patients receiving both low (n = 19) and hig...
AbstractObjectives. We sought to determine the electrophysiologic mechanisms explaining the efficacy...
AbstractObjectives. This study assessed the efficacy of the combination of sotalol and either quinid...
A double-blind, placebo-controlled, crossover, multicenter study was conducted to study the efficacy...
Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-...
AbstractSixty-five patients with symptomatic, drug-refractory, sustained ventricular tachycardia or ...
Fifty patients with recurrent sustained symptomatic ventricular tachycardia (43 patients) or ventric...
AbstractObjectives. This study evaluates the clinical efficacy of d,l-sotalol in patients with susta...
Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potenti...
o evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular t...
The anti-arrhythmic efficacy of sotalol, aβ-blocking agent which possesses class III anti-arrhythmic...
Sotalol, a class III antiarrhythmic drug (AAD) approved for use in ventricular arrhythmias, is being...
D, L-Sotalol is newly approved for the treatment of life-threatening ventricular arrhythmias. Severa...
Despite proven effectiveness in treating tachyarrhythmias, sotalol is proarrhythmic and can cause t...
ABSTRACT Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studi...
Although discovered more than two decades ago, the clinical applications of sotalol are still a matt...
AbstractObjectives. We sought to determine the electrophysiologic mechanisms explaining the efficacy...
AbstractObjectives. This study assessed the efficacy of the combination of sotalol and either quinid...
A double-blind, placebo-controlled, crossover, multicenter study was conducted to study the efficacy...
Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-...
AbstractSixty-five patients with symptomatic, drug-refractory, sustained ventricular tachycardia or ...
Fifty patients with recurrent sustained symptomatic ventricular tachycardia (43 patients) or ventric...
AbstractObjectives. This study evaluates the clinical efficacy of d,l-sotalol in patients with susta...
Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potenti...
o evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular t...
The anti-arrhythmic efficacy of sotalol, aβ-blocking agent which possesses class III anti-arrhythmic...
Sotalol, a class III antiarrhythmic drug (AAD) approved for use in ventricular arrhythmias, is being...
D, L-Sotalol is newly approved for the treatment of life-threatening ventricular arrhythmias. Severa...
Despite proven effectiveness in treating tachyarrhythmias, sotalol is proarrhythmic and can cause t...
ABSTRACT Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studi...
Although discovered more than two decades ago, the clinical applications of sotalol are still a matt...
AbstractObjectives. We sought to determine the electrophysiologic mechanisms explaining the efficacy...
AbstractObjectives. This study assessed the efficacy of the combination of sotalol and either quinid...
A double-blind, placebo-controlled, crossover, multicenter study was conducted to study the efficacy...